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Abstract
Follicular lymphoma is an incurable B-cell malignancy1 characterized by the t(14;18) and 
mutations in one or more components of the epigenome2,3. Whilst frequent gene mutations in 
signaling pathways, including JAK-STAT, NOTCH and NF-κB, have also been defined2–7, the 
spectrum of these mutations typically overlap with the closely-related diffuse large B cell 
lymphoma (DLBCL)6–13. A combination of discovery exome and extended targeted sequencing 
revealed recurrent somatic mutations in RRAGC uniquely enriched in FL patients (17%). More 
than half of the mutations preferentially co-occurred with ATP6V1B2 and ATP6AP1 mutations, 
components of the vacuolar H+-adenosine triphosphate ATPase (v-ATPase) known to be 
necessary for amino acid-induced mTORC1 activation. The RagC mutants increased raptor 
binding whilst rendering mTORC1 signaling resistant to amino acid deprivation. Collectively, the 
activating nature of the RRAGC mutations, their existence within the dominant clone and stability 
during disease progression supports their potential as an excellent candidate to be therapeutically 
exploited.
Follicular lymphoma (FL) is one of the commonest non-Hodgkin’s lymphomas (NHLs). 
Whilst the majority of affected individuals exhibit a characteristic protracted disease course 
with multiple relapses, others develop aggressive disease and histological transformation 
with shortened overall survival. Genome-wide profiling studies have primarily focused on 
single time-point analyses or the subset of patients that have undergone histological 
transformation in order to determine the genetic mediators of progression2,3. To gain further 
insight into the genetic diversity of FL, we undertook temporal analyses on individuals 
diagnosed with FL that underwent several relapse episodes without transformation. These 
data uncovered recurrent mutations in components of the mTORC1 signaling pathway, 
specific to FL.
Exome sequencing was performed on 24 tumors (from 5 patients) and matched 
constitutional DNA, with an average sequencing depth of 140x and 97.5% of the targeted 
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bases covered by >10-fold (Online Methods and Supplementary Table 1). The clinical 
course from diagnoses to last follow-up ranged from 12.5 to 25 years (Supplementary Table 
2 and Supplementary Fig. 1). A median of 94 non-synonymous mutations per tumor were 
identified and validated mutations of interest by a combination of Sanger and tagged-
amplicon sequencing (Supplementary Tables 3 and 4). Consistent with our earlier 
longitudinal study of paired FL and transformed FL2, tumors from the same individual 
confirmed a branched evolutionary pattern and demonstrated that all tumors evolve from a 
dominant ancestral clone (Supplementary Fig. 2). Moreover, mutations in KMT2D, 
CREBBP and MEF2B were present on the trunks of the phylogenetic trees in all five 
individuals, consistent with the role of epigenetic deregulation as critical early events in the 
majority of FLs2,3,14,15.
Remarkably, our data disclosed a novel finding of somatic non-silent mutations in the gene 
RRAGC, which encodes a Ras-related GTP-binding protein (RagC), occurring in four of the 
five cases. Notably, in cases B4 and B6, the RRAGC mutations (p.Pro118Leu and 
p.Lys74Arg) were conserved during disease progression whereas in cases B2 and B3, a 
convergent pattern of clonal selection was seen with different mutations occurring at 
different time points in the disease evolution (Fig. 1a). Copy number variation were rarely 
observed at the RRAGC locus, 1p34.3, in both our current data and previous single-
nucleotide polymorphism (SNP) array datasets2 (Supplementary Fig. 3). These together with 
the RRAGC variant allele frequencies (VAF) were consistent with heterozygous mutations 
(VAF range: 0.17–0.5), whilst clonality plots verified that the VAFs were comparable to 
those of early driver mutations demonstrating that the RRAGC mutations reside within the 
dominant clone of the tumor biopsies (Fig. 1b).
To determine the prevalence of RRAGC mutations, targeted sequencing was performed in an 
extension cohort of 141 FL samples (including the original 5 cases) and 32 cases with paired 
transformed FL. RRAGC mutations were present in 17% of cases (Table 1). The mutations 
were predominantly missense, with exception of two in-frame frameshift mutations, 
restricted to exons 1 and 2 (Fig. 1c and Supplementary Table 5). The clustering of mutations 
corresponded to the nucleotide-binding domain with hotspots centering on amino acids 
p.Ser75, p.Thr90, p.Try115, p.Asp116 and p.Pro118, residues highly conserved between 
species (Fig. 1c and Fig. 1d). In 10 patients with constitutional DNA, the somatic nature of 
the mutations was confirmed. To investigate the full complement of RRAGC mutations in 
other malignancies, we performed Sanger sequencing, restricting our analyses to exon 1 and 
2, in a further 329 related mature B-cell NHLs and 51 B-cell lymphoma cell lines alongside 
an analysis of publically available sequencing datasets. RRAGC mutations were absent in 
other hematological malignancies, including myeloid and other mature B-cell NHL entities 
(Table 1) with the exception of infrequent mutations in the closely-related DLBCL. We 
found that RRAGC was rarely mutated in non-hematological neoplasms (0.3% of nearly 
10,000 samples) included in the Cancer Genomics database (cBioportal)21, with the majority 
of mutations arising in residues beyond p.Pro118 (Supplementary Table 6). RRAGC 
mutations are therefore highly enriched in FL with their nature and frequency suggesting 
that the changes are likely to be functionally relevant in this lymphoma.
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RagC is one of four members of the Rag GTPase family in mammals, which form obligate 
heterodimers between RagA/B and RagC/D22,23. The Rag GTPases form a supercomplex on 
the lysosomal surface with Ragulator, the v-ATPase and SLC38A9 (Supplementary Fig. 4), 
essential for inducing mechanistic target of rapamycin complex 1 (mTORC1) activation in 
response to amino acid sufficiency24-31. Other members of the Rag GTPase family and 
mTORC1 components (RRAGA, RRAGB, RRAGD, MTOR, RPTOR and MLST8) were 
infrequently mutated (Supplementary Table 5). To expand this search, we examined our FL 
datasets to ascertain if other regulatory complexes upstream and downstream of Rag 
GTPases were subject to genetic aberrations. This approach uncovered mutations in two 
subunits of the v-ATPase complex, ATP6V1B2 and ATP6AP1. The v-ATPase complex 
resides within intracellular compartments such as the lysosome and is composed of two 
domains, a cytosolic V1 domain responsible for ATP hydrolysis and a transmembrane V0 
that enables proton translocation32. ATP6V1B2 is a non-catalytic subunit within the V1 
domain, and ATP6AP1 is thought to be an accessory subunit that regulates the function of 
the v-ATPase complex33. To assess the relationship between these v-ATPase subunit 
mutations, RRAGC and FL-associated genes, we resequenced our extension cohort of 141 
FL cases identifying 11.3% and 9.9% of cases with ATP6V1B2 and ATP6AP1 mutations, 
respectively (Fig. 2a and Supplementary Table 7, 8). Interestingly, mutations in RRAGC, 
ATP6V1B2 and ATP6AP1 showed strong correlations with more than half of the RRAGC 
mutations co-occurring with either ATP6V1B2 or ATP6AP1 (Fisher’s exact test, P < 
0.0001), whereas ATP6V1B2 and ATP6AP1 mutations were mutually exclusive. Mutations 
in ATP6V1B2 were all missense, with a hotspot at c.1199G>A; p.Arg400Gln representing 
80% of all mutations detected (Fig. 2b). In comparison, mutations in ATP6AP1 included 
both missense and frameshift mutations most localizing to the C-terminal end of the ATP-
synthase domain (Fig. 2c). Deep targeted sequencing (mean coverage 4655x) of 15 co-
mutated cases demonstrated no definitive hierarchy in mutation order of RRAGC and 
ATP6V1B2 or ATP6AP1 suggesting that both alterations are acquired concomitantly during 
similar clonal selective sweeps (Fig. 2d). Together, over a quarter of patients (27.4%; 39 of 
141 cases) had mutations in one or more of the three genes.
To begin understanding the pathogenic role of RRAGC mutations, we examined RNA-seq 
data in 13 FL cases (Supplementary Table 9) and identified 257 differentially expressed 
genes between mutated and wild-type cases (Supplementary Fig. 5a). There was no 
difference in RRAGC expression between mutated and wild-type cases (Supplementary Fig. 
5b). Gene set enrichment analyses (GSEA) showed that RRAGC-mutated cases were 
characterized by up-regulated expression for gene sets involved in translation regulation, 
well-known downstream mTOR targets34,35 (Supplementary Fig. 6 and Supplementary 
Table 10), implicating altered signaling as a consequence of these mutations.
The direct binding of Rag GTPase heterodimers to mTORC1 is a key event in the activation 
of mTORC1 by amino acids23–29. Under these conditions, the active Rag heterodimer, 
composed of GTP-loaded RagA/B bound to GDP-loaded RagC/D, directly interacts with 
raptor (Supplementary Fig. 4), a component of mTORC125. We first assessed the effects of 
8 RagC mutants detected in our FL series (p.Lys74Arg, p.Ser75Asn, p.Ser75Phe, 
p.Thr90Asn, p.Ile99Phe, p.Tyr115Arg, p.Asp116Gly and p.Pro118Leu) on their raptor 
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binding capacity by co-expressing each RagC mutant (RagCmut) together with wild-type 
RagB in HEK-293T cells. These RagB-RagCmut heterodimers co-immunoprecipitated 
substantially more endogenous raptor than a fully wild-type RagB-RagC heterodimer (Fig. 
3a). Importantly, the increased raptor binding was specific to the identified FL RRAGC 
mutations, as RagC mutations in other cancer types did not demonstrate the same capacity 
(Supplementary Fig. 7a). Interestingly, the increased raptor binding observed with the 
RagCmut was similar to that seen with RagC p.Ser75Asn, a previously characterized mutant 
with decreased affinity for GTP that therefore functions like a ‘GDP-bound’ mutant, 
mimicking the RagC conformation that is necessary for mTORC1 activation by amino 
acids25, 36–39 (Fig. 3a). The similar increase in raptor binding caused by the RagC mutants 
and RagC p.Ser75Asn provided the first indication that the RRAGC mutations observed in 
FL are likely activating. To examine the impact of these mutations in B-cell lymphomas, we 
stably expressed three recurring FL mutants (p.Ser75Phe, p.Thr90Asn and p.Trp115Arg) 
and the ‘GDP-binding’ mutant, RagC p.Ser75Asn, in four germinal center NHL cell lines 
(Karpas-422, Raji, OCI-Ly7 and OCI-Ly8) and these reaffirmed our findings of increased 
raptor binding over wild-type RagC (Fig. 3b and Supplementary Fig. 7b–d). To test the 
effects of the RagC mutants on mTORC1 signaling, we stably expressed these four mutants 
in HEK-293T cells. Overexpression of all four mutants increased mTORC1 activity, even 
under complete amino acid deprivation as detected by the phosphorylation of S6 kinase 1 
(S6K1), an established mTORC1 substrate (Supplementary Fig. 7e). Furthermore, all 
RagCmuts tested rendered mTORC1 signaling partially or fully insensitive to leucine or 
arginine deprivation, amino acids of particular importance for mTORC1 pathway 
activation 24, 40, 41 (Figs. 3c, 3d and Supplementary Fig. 7f, 7g). Similarly, in Karpas-422 
cells, overexpression of two mutants, p.Thr90Asn and p.Trp115Arg, but not wild-type 
RagC, led to increased mTORC1 signaling in the absence of leucine, validating the 
mTORC1 activating properties of the RagC mutants (Fig. 3e and Supplementary Fig. 7h).
To determine if RagC mutations affect their capacity to bind guanine nucleotides, we 
employed a specific in vitro assay in which nucleotide binding to purified Rag heterodimers 
could be assessed by purifying wild-type and mutant RagC in complex with a RagB mutant 
(p.Asp163Asn) that preferentially binds to xanthosine nucleotides. Employing this RagB 
mutant allowed us to measure guanine nucleotide binding to the RagC mutant only, even in 
the presence of RagB42,43. Two classes of RagC mutants emerged from this analysis. One 
class, including RagC Ser75Asn and Ser75Phe, had significantly decreased affinity for GTP 
in comparison to wild-type RagC, and a preference for binding GDP over GTP (Figs. 4a–b). 
These mutants are analogous to the Ras Ser17Asn mutant, which disrupts coordination of 
the magnesium cofactor leading to decreased affinity for all nucleotides37,38. Interestingly, 
this Ras mutant suppresses signaling, not through decreased GTP binding, but rather through 
its high affinity for ras guanine nucleotide exchange factors (GEFs), thus preventing guanine 
nucleotide exchange on wild-type Ras38, 44, 45. Further studies will be needed to uncover if 
the same mechanism is true for the RagC mutants, as a GEF for RagC has yet to be 
identified. The second class of mutants, Thr90Asn and Trp115Arg, display a slight 
preference for GDP binding over GTP, without an overall decrease in GTP binding in 
comparison to wild-type RagC (Fig. 4a, b). While the relative nucleotide affinity of these 
mutants is biased towards GDP, this may not account for their signaling effects in cells, as 
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intracellular GTP concentrations are 10–20 times higher than those of GDP46. Importantly, 
the levels of RagC were consistent in our assays indicating that the variation in nucleotide 
binding cannot be accounted for by differences in protein levels (Fig. 4c). While this second 
class of mutants may activate the mTORC1 pathway through mechanisms not involving 
changes in nucleotide loading, further work is needed to uncover the exact mechanism 
through which they lead to increased raptor binding.
As the v-ATPase complex is functionally linked with the Rag GTPases and Ragulator in 
sensing amino acids and activating mTORC1 signaling29, the co-existence of RRAGC with 
either ATP6V1B2 or ATP6AP1 mutations raises the question of a functional epistasis. ATP-
hydrolysis and the v-ATPase rotator conformation are crucial for relaying the amino acid 
signal from the lysosomal lumen to the Rag GTPases29 and therefore, our working 
hypothesis is that mutations in these v-ATPase subunits help convey a ‘false’ amino acid 
sufficiency signal or alter interactions between v-ATPase, Ragulator and the Rag GTPases, 
which requires experimental clarification.
In conclusion, our study identifies frequent mutations in components of the lysosome-centric 
mTORC1 signaling cascade in FL. We demonstrate that RRAGC mutants confer a gain-of-
function mechanism by bypassing the amino acid deprivation state to activate mTORC1 
signaling. Together, the emergence of frequent activating RRAGC mutations that are 
clonally represented and maintained during progression is particularly valuable and might be 
exploited as a therapeutic target, however, its utility as a predictive biomarker of mTOR 
inhibitor sensitivity warrants further investigation.
ONLINE METHODS
Patients and samples
Samples were obtained from individuals with FL and non-FL tumors following approval 
from the Institutional Review Board and local ethics committee of all participating centers. 
Informed written consent was obtained from all individuals. The discovery cohort 
(Supplementary Table 2 and Supplementary Fig. 1) comprised five patients who had not 
undergone histologic transformation and selected on the basis of available fresh frozen 
tumor lymph node biopsies, matched constitutional DNA and samples from multiple disease 
episodes. The clonality between tumor biopsies obtained from multiple disease episodes 
from an individual patient were confirmed by BCL2-IGH breakpoint analysis as previously 
described2. The FL validation cohort (Supplementary Table 11) comprised either diagnostic 
or relapse FL (n = 141 cases) or paired FL-tFL tumor biopsies (n=32 cases) obtained from 
two centers (Barts Cancer Institute and University of Southampton). The clinical 
characteristics of the cohort are shown in Supplementary Table 12. Non-FL tumors for 
validation included DNA from 174 DLBCL, 96 CLL and 48 SMZL tumors. Histology of all 
tumors was confirmed by pathological review.
Whole exome sequencing and analysis
Whole exome capture libraries were constructed from 2–3ug of tumor or constitutional 
DNA after shearing, end repair, phosphorylation and ligation to barcoded sequencing 
adaptor, using the Human All Exon V5 SureSelect XT (Agilent Technologies). Enriched 
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exome libraries were multiplexed and sequenced on the HiSeq 2500 (Illumina) to generate 
100bp paired-end reads. Sequencing metrics are provided in Supplementary Table 1. The 
processing and analysis of whole exome sequencing data were performed using our previous 
pipeline2. Briefly, sequencing reads were aligned to the reference genome hg19, using 
Burrows-Wheeler Aligner (BWA)48. Local alignments and base quality scores were 
adjusted using the Genome Analysis Toolkit (GATK)49 version 2.5.2.
Variant detection and mutation annotation
Somatic SNVs and indels were identified using the Strelka pipeline as previously 
described2. For each sample, the number of reads supporting the reference and variant 
alleles at each position was extracted. VAFs were calculated by dividing the number of 
supporting variant reads to the total reads obtained. To improve the variant calls across all 
the tumors from the same patient, identified variants were further genotyped and verified 
across all tumors and matched normal using VarScan2’s multi-sample calling method 
‘mpileup2cns’50, based on reads with mapping quality > 30 and minimum base quality of 20 
at the targeted site. Annotation of variants was attained using the SNPnexus tool51.
Sanger sequencing of genomic DNA
Direct bidirectional Sanger sequencing of RRAGC exon 1 and 2, ATP6V1B2 (all exons), 
ATP6AP1 (all exons) and ATP6AP2 (all exons) from genomic DNA from tumors and 
matched normal samples was performed following direct PCR amplification, using specific 
primers, and enzymatic clean up using Exo-Sap (USB Corporation).
Phylogenetic analyses
Evolutionary trees were reconstructed for each individual based on the distance matrix 
between GL, FL and relapse FL samples derived from the numbers of somatic non-
synonymous variants from each biopsy, using the Neighbor-Joining algorithm52 
implemented in the PHYLIP package as previously reported2. Once the consensus 
phylogenetic tree was determined, it was redrawn starting from GL leading to the putative 
CPC, then to FL and subsequent relapse FL samples, with the branch length proportional to 
the number of somatic changes i.e. genetic distance between the samples.
Copy number variation of the RRAGC locus
Copy number variation and copy neutral loss of heterozygosity for ATP6AP1, ATP6V1B2, 
RRAGC and TNFRSF14 gene loci were extracted from our previous SNP array analyses 
using the methodology previously described2. To detect copy number imbalances from our 
discovery WES data, VarScan2 “copynumber” module was first employed, using the 
minimum read coverage as 20, and both mapping and base qualities as ≥ 20 for usable reads, 
to generate raw copy number calls. Raw calls were adjusted for GC content and re-centered 
to 0 based on the modal LogR value determined by kernel density estimates, using VarScan2 
“copyCaller” module. Outliers were identified and modified using the data winsorizing 
procedure. The DNAcopy R Bioconductor package (Seshan VE and Olshen A. DNAcopy: 
DNA copy number data analysis. R package version 1.40.0) was employed to identify joint 
segments of LogR values using the circular binary segmentation (CBS) algorithm. To 
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identify regions of LOH, variants (including SNPs and short indels) against the reference 
genome were first identified for paired normal and tumour samples using VarScan2. Next, 
B-allele frequency (BAF) files were created, allowing the minimum read depth of 10 for 
both tumour and normal. The ASCAT R package53 was then used to assess CNAs and LOH 
regions, using the logR and BAF files derived from VarScan variant calls, with the depth 
information normalized by dividing the depth of each variant by the median depth across all 
variants.
Targeted sequencing of Rag GTPases and mTORC1-associated genes
Target-specific primers for FL-associated genes2 and 7 mTORC1-associated genes (RRAGA, 
RRAGB, RRAGC, RRAGD, MTOR, RPTOR and MLST8) were custom designed using 
Fluidigm’s D3 Assay design service. Targeted enrichment was performed by Access Array 
(Fluidigm) in a multiplex format using genomic DNA (50ng) according to the 
manufacturer’s Multiplex Amplicon Tagging Protocol. The multiplexed library pools were 
sequenced on the Illumina Miseq platform. All samples were screened in duplicate with the 
inclusion of normal tonsil DNA controls in each run. Variants were called and annotated as 
previously described2. In brief, reads were aligned to hg19 using BOWTIE254. SAMtools55 
were used to generate sorted BAM files and the VarScan2 tool was used to examine the 
pileup file to call variants.
Deep tagged-amplicon sequencing for RRAGC, ATP6V1B2 and ATP6AP1 genes
Universal adapter sequences were tagged to the 5′ and 3′ end of target-specific primers of 
approximately 200±20bp in length. Based on our initial experiments that showed clustering 
of variants within specific exons of the 3 genes, subsequent analyses were restricted to 
RRAGC (exons 1 and 2), ATP6V1B2 (exons 11 and 12) and ATP6AP1 (exons 9 and 10). 
Primer sequences are shown in Supplementary Table 13. 100ng of genomic DNA were 
amplified in 2 to 4-plex PCR reactions using non-overlapping tagged-primers with the 
HotStar Taq Plus kit (Qiagen) under limited cycling conditions. Amplified PCR fragments 
were subsequently pooled in equimolar ratios by sample and prepared for sequencing with 
the attachment sample specific indexes and Illumina adaptor sequences. Indexed libraries 
were pooled and sequenced on a single lane of an Illumina MiSeq instrument using the V2 
300-cycles Miseq reagent kit (Illumina) generating 150-bp paired end reads. Each sample 
was screened in duplicate. Variant calling and annotation are as described above.
RNA-sequencing analysis
RNA-seq data for all 13 FL samples (5 mutants and 8 wild-type) were downloaded from the 
International Cancer Genome Consortium (ICGC) data repository (see URLs). Details of the 
samples are summarized in Supplementary Table 9. Raw read counts for all annotated 
ENSEMBL genes across the 13 samples were extracted from the “exp_seq.MALY-DE.tsv” 
file in the ICGC data repository. Only genes that achieved at least one read count per million 
reads (CPM) in at least five samples were selected, with these criteria producing 22,126 
filtered genes in total. After applying scale normalization, read counts were converted to 
log2-cpm using the voom function56 with associated weights ready for linear modeling. 
Differential gene expression (DGE) analyses between mutant and wild-type groups were 
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further performed using the limma R package, which powers DGE analyses for RNA-seq 
and microarray data 57. A double threshold of raw p value <0.01 and an absolute fold change 
> 2 were used to define significantly differentially expressed (DE) genes (Supplementary 
Figure 5a). Based on the t-statistic of filtered genes from the Iimma test, GSEA was 
performed against the predefined curated gene sets (c2) acquired from the MSigDB 
collection58, including KEGG and Reactome gene sets. Top significantly enriched gene sets 
were selected based on FDR q-value <0.05 (Supplementary Table 10).
Materials
Reagents were obtained from the following sources: HRP-labeled anti-mouse and anti-rabbit 
secondary antibody from Santa Cruz Biotechnology; antibodies to phospho-T389 S6K1, 
S6K1, mTOR, and FLAG epitope from Cell Signaling Technology; antibody to the HA 
epitope from Bethyl laboratories; antibody to raptor from Millipore. RPMI, FLAG M2 
affinity gel, GTP, GDP, and amino acids from Sigma Aldrich; XDP and XTP from Jena 
Biosciences; [3H]-labeled GTP and GDP from Perkin Elmer; DMEM from SAFC 
Biosciences; Complete Protease Cocktail from Roche; Inactivated Fetal Calf Serum (IFS) 
and simply blue stain from Invitrogen; amino acid-free RPMI from US Biologicals.
Cell lines and tissue culture
HEK-293T cells were cultured in DMEM 10% IFS supplemented with 2 mM glutamine, 
penicillin (100 IU/mL), and streptomycin (100 μg/mL). Karpas-422, Raji, OCI-Ly7, and 
OCI-Ly8 cells were cultured in RPMI 10% IFS supplemented with 2 mM glutamine, 
penicillin (100 IU/mL), and streptomycin (100 μg/mL). All cell lines were maintained at 
37°C and 5% CO2.
Virus production and viral transduction
The production of lentiviruses was achieved by transfection of viral HEK-293T cells with 
pLJM60-FLAG-metap2 or pLJM60-FLAG-RagC (wild-type or mutant) constructs, with the 
VSV-G envelope and CMV ΔVPR packaging plasmids. Similarly, the production of 
retroviruses for infection of the Karpas-422 cells was achieved by transfection of viral 
HEK-293T cells with pMXs-RagC (wild-type or mutant) constructs, with the VSV-G 
envelope and gag/pol packaging plasmids. Twenty-four hours after transfection, the media 
was changed to DME with 30% IFS. After another 24 hours, the virus-containing 
supernatant was collected from the cells and passed through a 0.45 μm filter. Target cells 
were plated in 6-well plates with virus containing media and 8 μg/mL polybrene. Spin 
infections were performed by centrifugation at 2,200 rpm for 1 hour. Twenty-four hours 
later, the media was changed to fresh media containing either puromycin (when infected 
with the lentivirus) or blasticidin (when infected with the retrovirus) for selection.
Cell lysis and immunoprecipitation
Cells were rinsed once with ice-cold PBS and immediately lysed with Triton lysis buffer 
(1% Triton, 10 mM β-glycerol phosphate, 10 mM pyrophosphate, 40 mM Hepes pH 7.4, 2.5 
mM MgCl2 and 1 tablet of EDTA-free protease inhibitor [Roche] (per 25 ml buffer). The 
cell lysates were centrifuged at 13,000 rpm in a microcentrifuge at 4°C for 10 minutes. For 
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anti-FLAG-immunoprecipitations, the FLAG-M2 affinity gel was washed three times with 
lysis buffer. 30 μl of a 50% slurry of the affinity gel in lysis buffer was then added to cleared 
cell lysates and rotated for 2 hours at 4°C. The beads were washed once with lysis buffer 
and 3 times with lysis buffer containing 500 mM NaCl after the incubation. 
Immunoprecipitated proteins were denatured by the addition of 50 μl of sample buffer and 
boiled for 5 minutes as described24, resolved by 8%–16% SDS-PAGE, and analyzed by 
immunoblotting.
For co-transfection experiments in HEK-293T cells, 2 million cells were plated in 10 cm 
culture dishes. Twenty-four hours later, cells were transfected via the polyethylenimine 
method59 with the pRK5-based cDNA expression plasmids indicated in the figures in the 
following amounts: 800 ng Flag-Metap2 or 400 ng Flag-RagC (wild-type and mutants); 400 
ng of RagB (wild-type and mutants). The total amount of plasmid DNA in each transfection 
was normalized to 5 μg with empty pRK5. Thirty-six hours after transfection, cells were 
lysed as described above.
For experiments that required amino acid, leucine, or arginine starvation or restimulation, 
cells were treated as previously described35. Briefly, cells were incubated in amino acid, 
leucine, or arginine free RPMI for 50 minutes and then stimulated with amino acids, leucine, 
or arginine for 10 minutes.
Nucleotide binding assays
40 pmols of FLAG-RagC (wild-type or mutant)-HA-RagBD163N were loaded with either 8 
μCi of [3H]GDP or 8 μCi of [3H]GTP (5–20 Ci/mmol) and co-loaded with either 62.5 nM 
XDP or 62.5 nM XTP in a total volume of 80ul of CHAPS buffer, supplemented with 2.5 
mM DTT, 10 μg BSA, and 6.25 mM EDTA. The CHAPS buffer contained 0.3% CHAPS, 
40 mM HEPES [pH 7.4], and 30 mM NaCl. The complexes were rotated for 10 minutes at 
room temperature and then stabilized with 25 mM MgCl2, rotated for another 10 minutes at 
room temperature, and then incubated on ice for 1 hour to allow the binding reaction to 
occur. 10 μl samples were taken, in triplicate, and spotted on nitrocellulose filters, which 
were washed three times with 1 ml of wash buffer (1.5% CHAPS, 40 mM HEPES [pH 7.4], 
150 mM NaCl, and 5 mM MgCl2). Filter-associated radioactivity was quantified using a 
TriCarb scintillation counter (PerkinElmer).
Statistical analysis
Fisher’s exact tests were used for comparison between two groups. For analysis of the 
nucleotide binding assay groups, two-tailed t tests were used. P values of less than 0.05 were 
considered to indicate statistical significance.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Identification of frequent RRAGC mutations in FL. (a) RRAGC mutations show two 
different patterns of conservation in successive tumor biopsies during FL progression in the 
discovery WES cases: mutation stability and convergent evolution. (b) Variant allele 
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frequency (VAF) distribution and density for all the non-synonymous mutations identified in 
the 5 WES cases. In each case, the first available biopsy is depicted, with the exception of 
B3 where two time points are illustrated (B3_FL1 and B3_FL8). (c) Schema of the protein 
domain and locations of the RRAGC mutations identified in this study (NCBI protein 
reference sequence: NP_071440.1). Thirty-seven mutations affecting 32 cases. ‘^’ denotes a 
second RRAGC mutation occurring in a different disease event from the same patient. ‘*’ 
represents a second RRAGC mutation within the same biopsy of a particular patient. 
Multiple circles for the same amino acid represent multiple cases with mutations affecting 
the same residue. (d) Sequence alignment of a section of the RRAGC nucleotide binding 
domain. Conserved residues across all the listed species is indicated by an asterisk (*). The 
location of the GTP/GDP binding sites are indicated by the red horizontal bar (locations: aa 
68–75; and aa 116–120) whilst the recurrent hotspot residues are highlighted by the light 
blue vertical panel.
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Figure 2. 
Frequent and co-occurring mutations in ATP6V1B2 and ATP6AP1. (a) The heatmap shows 
the distribution of mutations in RRAGC, ATP6V1B2, ATP6AP1 and other known FL-
associated genes in 141 FL cases. Each column represents an individual case and each row 
denotes a specific gene. Red indicates the presence of mutations, and light grey indicates the 
absence. (b) Schema of the protein domain and locations of the identified ATP6V1B2 
mutations (NCBI protein reference sequence: NP_001684.2). (c) Schema of the protein 
domain and locations of the identified ATP6AP1 mutations (NCBI protein reference 
sequence: NP_001174.2). Red circles represent missense mutations, blue triangles are in-
frame indels and green triangles are out-of-frame indels. The ‘#’ indicates mutations 
occurring in the same case. (d) Comparison of the allele frequencies in 26 co-mutated 
(RRAGC vs. ATP6V1B2 and RRAGC vs. ATP6AP1) samples (comprising 15 cases, some 
with multiple biopsies). Male cases are marked with an asterisk (*) and demonstrate 
expected increases in allelic frequencies of ATP6AP1 mutations as the gene locus resides on 
the X chromosome.
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Figure 3. 
Effects of RagC mutants on mTORC1 signaling. (a) Rag heterodimers containing the RagC 
mutants co-immunoprecipitate the largest amounts of raptor, an mTORC1 component, 
similar to the previously characterized RagCS75N mutant. Anti-FLAG immunoprecipitates 
were collected from HEK-293T cells transiently expressing the indicated cDNAs, and cell 
lysates and immunoprecipitates were analyzed by immunoblotting. RagBQ99L and 
RagCQ120L are ‘GTP-locked’ mutants36, 47, while RagCS75N and RagBT54N function as 
‘GDP-binding’ mutants25, 36–39. (b) Two recurrent mutants from FL, RagCT90N and 
RagCW115R, and the previously characterized RagCS75N mutant co-immunoprecipitate more 
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endogenous raptor than wild-type RagC in Karpas-422 cells, a B cell lymphoma line of 
germinal center origin. Anti-FLAG immunoprecipitates from Karpas-422 cells stably 
expressing the indicated proteins were collected and analyzed as in (a). (c) Stable 
overexpression of RagCS75N, RagCS75F, RagCT90N, and RagCW115R render cells partially or 
fully insensitive to leucine deprivation. HEK-293T cells stably expressing the indicated 
proteins were starved of leucine for 50 minutes and re-stimulated with leucine for 10 
minutes. Cell lysates were analyzed by immunoblotting for the indicated proteins. (d) Stable 
overexpression of the indicated RagC mutants leads to an increase in mTORC1 signaling in 
the absence of arginine. HEK-293T cells stably expressing the indicated proteins were 
starved of arginine for 50 minutes, restimulated with arginine for 10 minutes, and analyzed 
as in (b). (e) Stable overexpression of the indicated RagC mutants, but not wild-type RagC, 
leads to increased mTORC1 signaling in the absence of leucine in a B cell lymphoma line. 
Karpas-422 cells stably expressing the indicated proteins were treated and analyzed as in 
(b).
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Figure 4. 
RagC mutants alter the affinity of nucleotide binding. (a) Three RagC mutants exhibit 
increased GDP binding, while RagCS75F decreased GDP binding. Nucleotide binding assays 
were performed with the indicated RagC heterodimer incubated with [3H]GDP and binding 
assessed using a filter-binding assay. Each value represents the normalized mean +/− SD for 
n = 3. Statistical differences are assessed comparing each sample to the binding observed 
with the RagB-RagC wild-type heterodimer. (b) RagCS75N and RagCS75F significantly 
decrease GTP binding, while RagCT90N does not affect GTP binding with RagCW115R 
slightly increasing this activity. Nucleotide binding assays were performed as in (B) but 
incubated with [3H]GTP. Each value represents the normalized mean +/− SD for n = 3. 
Statistical differences are assessed comparing each sample to the binding observed with the 
RagB-RagC wild-type heterodimer. (c) RagB and RagC protein levels in the nucleotide 
binding assays are consistent. Aliquots of the purified Rag heterodimers used in the 
nucleotide binding assays were resolved on an SDS-PAGE gel and stained with Coomassie. 
*P<0.05; **P<0.01; ***P<0.005.
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Table 1
Frequency of RRAGC mutations in lymphoma and other hematological malignancies
Tumor type Occurrence No./total No. Frequency
FL 25/141 17.7%
 Diagnostic 13/94 13.8%
 Relapse 12/47 25.5%
FL and tFL pairs 6/32# 18.8%
DLBCL^ 3/174 1.7%
 GCB 1/67 1.5%
 ABC 1/43 2.3%
 PMBL 1/29 3.4%
 U 0/35 0%
DLBCL* 1/185 0.5%
B cell lymphomas
 Burkitt lymphoma* 0/42 0%
 CLL/SLL^ 0/96 0%
 CLL* 0/258 0%
 MCL* 0/29 0%
 SMZL^ 0/48 0%
 Other B-cell lymphomas 0/48 0%
Cell lines (B-NHL) 2/51 3.9%
Other hematological malignancies
 AML* 0/200 0%
 CML* 0/129 0%
 MM* 0/203 0%
Benign reactive lymph nodes 0/10 0%
tFL, transformed follicular lymphoma; DLBCL, diffuse large B cell lymphoma; GCB, germinal center B-cell subtype DLBCL defined by gene-
expression profiling (GEP); ABC, activated B-cell subtype of DLBCL defined by GEP; PMBL, primary mediastinal B-cell lymphoma defined by 
GEP; U, unclassifiable by GEP; CLL, chronic lymphocytic leukemia; MCL, mantle cell lymphoma; SMZL, splenic marginal zone lymphoma; 
AML, acute myeloid leukemia; CML, chronic myeloid leukemia; MM, multiple myeloma.
#
comprising 5 cases with mutations in both FL and tFL and 1 case with only the tFL sample
^Sanger sequencing restricted to RRAGC exon 1 and 2
*
Mined from publicly available cancer genome datasets (see URL)10,12,13,16–20,
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